Search by Drug Name or NDC
NDC 50090-4364-00 INVOKANA 300 mg/1 Details
INVOKANA 300 mg/1
INVOKANA is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by A-S Medication Solutions. The primary component is CANAGLIFLOZIN.
MedlinePlus Drug Summary
Canagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Canagliflozin is also used to reduce the risk of stroke, heart attack, or death in people who have type 2 diabetes along with heart and blood vessel disease. Canagliflozin is also used to reduce the risk of end-stage kidney disease, worsening of kidney function, needing to be hospitalized for heart failure, and cardiovascular death in people who have type 2 diabetes along with severe kidney disease. Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Canagliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 50090-4364-00Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Canagliflozin
Product Information
NDC | 50090-4364 |
---|---|
Product ID | 50090-4364_8f7706b7-8c1b-4c13-bb18-3ec25c98425f |
Associated GPIs | 27700020000330 |
GCN Sequence Number | 070792 |
GCN Sequence Number Description | canagliflozin TABLET 300 MG ORAL |
HIC3 | C4D |
HIC3 Description | ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT2(SGLT2) INH |
GCN | 34441 |
HICL Sequence Number | 040171 |
HICL Sequence Number Description | CANAGLIFLOZIN |
Brand/Generic | Generic |
Proprietary Name | INVOKANA |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | canagliflozin |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, FILM COATED |
Route | ORAL |
Active Ingredient Strength | 300 |
Active Ingredient Units | mg/1 |
Substance Name | CANAGLIFLOZIN |
Labeler Name | A-S Medication Solutions |
Pharmaceutical Class | P-Glycoprotein Inhibitors [MoA], Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA204042 |
Listing Certified Through | 2024-12-31 |
Package
NDC 50090-4364-00 (50090436400)
NDC Package Code | 50090-4364-0 |
---|---|
Billing NDC | 50090436400 |
Package | 90 TABLET, FILM COATED in 1 BOTTLE (50090-4364-0) |
Marketing Start Date | 2019-06-17 |
NDC Exclude Flag | N |
Pricing Information | N/A |